reports
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)...
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
- Jonathan Moreland
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
POST POST HOLDINGS INC.
NWBI NORTHWEST BANCSHARES INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GLP GLOBAL PARTNERS LP
CALX CALIX NETWORKS
GAM GENERAL AMERICAN INVESTORS CO. INC.
PBI PITNEY BOWES INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
PED PEDEVCO CORP
VRCA VERRICA PHARMACEUTICALS
ONEW ONEWATER MARINE
BBWI BATH & BODY WORKS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
QDEL QUIDEL CORP
J JACOBS SOLUTIONS INC.
EBC EASTERN BANKSHARES INC
SMRT SMARTRENT INC
GTE GRAN TIERRA ENERGY INC.
MNR MACH NATURAL RESOURCES LP
RMI RIVERNORTH OPPOR MUN INC FD INC
Verrica Pharmaceuticals Announces Private Placement Financing of $50 M...
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica’s Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company ...
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results – Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH...
Annexon Announces Closing of Public Offering and Full Exercise of Unde...
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the unde...
Annexon Announces Pricing of $75 Million Public Offering of Common Sto...
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investor...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Fun...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. In addit...
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progre...
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 20...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 C...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting – Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315’s ...
Verrica Pharmaceuticals Receives Positive Feedback from the European M...
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union – EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa...
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2...
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immu...
Verrica Pharmaceuticals Announces That Development Partner, Torii Phar...
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum – Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics co...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Ann...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Confer...
Annexon Biosciences to Participate in Upcoming September Investor Conf...
Annexon Biosciences to Participate in Upcoming September Investor Conferences BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 3...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq L...
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progr...
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Ki...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.